Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial - PubMed
a day ago
- #clinical trial
- #nasopharyngeal carcinoma
- #antibody-drug conjugate
- MRG003 (becotatug vedotin), an EGFR-targeted ADC, was evaluated in a phase IIa trial for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).
- The study included 61 patients with a median follow-up of 21.9 months, showing an IRC-assessed ORR of 42% and DCR of 81%.
- Median DoR was 8.0 months, PFS was 5.8 months, and OS was 15.8 months (25.2 months for the 2.3 mg/kg dose group).
- In patients who failed PD-1/L1 inhibitors and ≥2 prior chemotherapy lines, ORR was 30% and DCR was 76%.
- Grade ≥3 treatment-related adverse events occurred in 39% of patients, with no treatment-related deaths reported.
- MRG003 demonstrated promising efficacy and manageable safety in pretreated R/M NPC patients.
- This is the first long-term evaluation of an EGFR-targeted ADC in this patient population.
- The study was supported by Shanghai Miracogen Inc, a subsidiary of Lepu Biopharma Co., Ltd.